AR075411A1 - Derivados de triazolo[1,5-a]piridina como inhibidores de kinasa. - Google Patents
Derivados de triazolo[1,5-a]piridina como inhibidores de kinasa.Info
- Publication number
- AR075411A1 AR075411A1 ARP100100400A ARP100100400A AR075411A1 AR 075411 A1 AR075411 A1 AR 075411A1 AR P100100400 A ARP100100400 A AR P100100400A AR P100100400 A ARP100100400 A AR P100100400A AR 075411 A1 AR075411 A1 AR 075411A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently
- hydrogen
- heteroaryl
- aryl
- Prior art date
Links
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical class C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- LENLQGBLVGGAMF-UHFFFAOYSA-N tributyl([1,2,4]triazolo[1,5-a]pyridin-6-yl)stannane Chemical compound C1=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=NN21 LENLQGBLVGGAMF-UHFFFAOYSA-N 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 101100295741 Gallus gallus COR4 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000002207 retinal effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000026726 vitreous disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
En particular se refieren al tratamiento o la mejora de un trastorno mediado por la cinasa, el cual incluye enfermedades cardiovasculares, diabetes, trastornos asociados con la diabetes, enfermedades inflamatorias, trastornos inmunologicos, cáncer y enfermedades de la vista tales como retinopatías o degeneracion macular u otras enfermedades vítreo retinales y similares. Reivindicacion 1: Los compuestos que tienen la estructura (1) como así también la sal, el hidrato o el solvato farmacéuticamente aceptable de los mismos en la cual A1 y A2 es N o C, con la condicion de que uno entre A1 o A2 sea N y uno entre A1 o A2 sea carbono, R1 y R2 son hidrogeno, arilo, heteroarilo, alquilo C1-4, -CN, -halogeno, -CF3, -OR4, R3 es hidrogeno, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, alquilo C1-4, -CN, -CF3, -OR4, -OCOR4, -COR4, -NR4R5, -NR4COR5, -NR4COOR5, -(alquilo C1-4)OR4, -(alquilo C1-4)COR4, -(alquilo C1-4)NR4R5, -(alquilo C1-4)NR4COR5, -(alquilo C1-4)NR4COOR5, X es una union o (CH2)aW(CH2)b, (CH2)aW(CH2)bY(CH2)c o- [(CH2)aW(CH2)b)m-(Z)e-[(CH2)cY(CH2)d]n en la cual a, b, c y d son independientemente 0, 1, 2 o 3, e es 0, 1 o 2 y n y m son independientemente 0 o 1 y W es -CO-,-O-, -SO2-,-CH2-, -CHOH-, -NR6-, NR7CONR8 o NR7SO2NR8 e Y es -CO-, -O-, -SO2-, -CH2-, -CHOH- o -NR6, NR7CONR8 o NR7SO2NR8 y Z se selecciona entre el grupo que consiste en cicloalquilo, heterocicloalquilo, arilo y heteroarilo y cuando e es 2, entonces cada una de las partes Z se seleccionan independientemente entre sí; R4, R5 y R6 son independientemente hidrogeno, alquilo C1-4 y donde R4 y R5 juntos pueden formar un anillo compuesto por entre 5 y 7 miembros, R7 y R8 son independientemente hidrogeno, alquilo C1-4 y donde R7 y R8 juntos pueden formar un anillo compuesto por entre 5 y 7 miembros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09360013 | 2009-02-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075411A1 true AR075411A1 (es) | 2011-03-30 |
Family
ID=42229029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100400A AR075411A1 (es) | 2009-02-13 | 2010-02-12 | Derivados de triazolo[1,5-a]piridina como inhibidores de kinasa. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20120041195A1 (es) |
| EP (1) | EP2396324A1 (es) |
| JP (1) | JP2012517971A (es) |
| KR (1) | KR20110116160A (es) |
| CN (1) | CN102317288A (es) |
| AR (1) | AR075411A1 (es) |
| BR (1) | BRPI1008850A2 (es) |
| CA (1) | CA2751517A1 (es) |
| CL (1) | CL2011001947A1 (es) |
| CO (1) | CO6420343A2 (es) |
| CR (1) | CR20110386A (es) |
| DO (1) | DOP2011000248A (es) |
| EA (1) | EA201101188A1 (es) |
| EC (1) | ECSP11011250A (es) |
| HN (1) | HN2011002095A (es) |
| IL (1) | IL214426A0 (es) |
| MX (1) | MX2011008549A (es) |
| NI (1) | NI201100151A (es) |
| NZ (1) | NZ594508A (es) |
| PE (1) | PE20120110A1 (es) |
| SG (1) | SG173610A1 (es) |
| TN (1) | TN2011000379A1 (es) |
| WO (1) | WO2010092041A1 (es) |
| ZA (1) | ZA201105896B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1009637A2 (pt) | 2009-06-05 | 2019-04-30 | Cephalon, Inc | composto, composição e uso de um composto |
| EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
| EP2343297A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| EP2343295A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridine derivates |
| UY33452A (es) * | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
| AR081960A1 (es) * | 2010-06-22 | 2012-10-31 | Fovea Pharmaceuticals Sa | Compuestos heterociclicos, su preparacion y su aplicacion terapeutica |
| SI2699575T1 (sl) | 2011-04-21 | 2015-10-30 | Bayer Intellectual Property Gmbh | Triazolopiridini |
| WO2012160029A1 (en) | 2011-05-23 | 2012-11-29 | Bayer Intellectual Property Gmbh | Substituted triazolopyridines |
| UA112096C2 (uk) | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
| KR20130091464A (ko) | 2012-02-08 | 2013-08-19 | 한미약품 주식회사 | 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체 |
| ES2605946T3 (es) | 2012-03-14 | 2017-03-17 | Bayer Intellectual Property Gmbh | Imidazopiridazinas sustituidas |
| BR112015000308A2 (pt) | 2012-07-10 | 2017-06-27 | Bayer Pharma AG | método para preparo de triazolopiridinas substituídas |
| WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| JP2016526534A (ja) | 2013-06-11 | 2016-09-05 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換トリアゾロピリジンのプロドラッグ誘導体 |
| AU2020385513A1 (en) * | 2019-11-22 | 2022-07-14 | Medshine Discovery Inc. | Pyrimidopyrrole spiro compounds and derivatives thereof as DNA-PK inhibitors |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6056684B2 (ja) | 1977-11-07 | 1985-12-11 | 東興薬品工業株式会社 | 点眼剤 |
| US4271143A (en) | 1978-01-25 | 1981-06-02 | Alcon Laboratories, Inc. | Sustained release ophthalmic drug dosage |
| US4407792A (en) | 1979-05-09 | 1983-10-04 | Alcon Laboratories, Inc. | Sustained release ophthalmic drug dosage |
| JPH0830004B2 (ja) | 1983-11-14 | 1996-03-27 | コロンビア ラボラトリーズ インコーポレイテッド | 生物接着性組成物およびそれにより治療する方法 |
| US5041434A (en) | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
| CA2386955A1 (en) | 1999-11-22 | 2001-05-31 | Warner-Lambert Company | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| US7268136B2 (en) * | 2002-12-18 | 2007-09-11 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| ATE433967T1 (de) | 2003-01-17 | 2009-07-15 | Warner Lambert Co | 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation |
| CN1897950A (zh) * | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| AU2004281154A1 (en) | 2003-10-16 | 2005-04-28 | Novartis Vaccines And Diagnostics, Inc. | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer |
| NZ551027A (en) | 2004-04-08 | 2011-01-28 | Targegen Inc | Benzotriazine inhibitors of kinases |
| JP5275628B2 (ja) | 2004-08-25 | 2013-08-28 | ターゲジェン インコーポレーティッド | 複素環式化合物および使用方法 |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| AU2006227628A1 (en) | 2005-03-16 | 2006-09-28 | Targegen, Inc. | Pyrimidine compounds and methods of use |
| WO2006118256A1 (ja) | 2005-04-28 | 2006-11-09 | Kyowa Hakko Kogyo Co., Ltd. | 2-アミノキナゾリン誘導体 |
| WO2006133411A1 (en) | 2005-06-08 | 2006-12-14 | Targegen, Inc. | Methods and compositions for the treatment of ocular disorders |
| WO2007067537A1 (en) * | 2005-12-07 | 2007-06-14 | Osi Pharmaceuticals, Inc. | Pyrrolopyridine kinase inhibiting compounds |
| PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| SG174086A1 (en) * | 2006-08-30 | 2011-09-29 | Cellzome Ltd | Triazole derivatives as kinase inhibitors |
| KR101079520B1 (ko) * | 2006-10-20 | 2011-11-03 | 아이알엠 엘엘씨 | Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 수용체를 조절하기 위한 조성물 및 방법 |
| TW200829566A (en) | 2006-12-08 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
| EA200900819A1 (ru) | 2006-12-22 | 2010-02-26 | Новартис Аг | Хиназолины для ингибирования pdk1 |
| GB0719803D0 (en) * | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CA2727036C (en) * | 2008-06-20 | 2017-03-21 | Genentech, Inc. | Triazolopyridine jak inhibitor compounds and methods |
| SG178807A1 (en) * | 2008-06-20 | 2012-03-29 | Genentech Inc | Triazolopyridine jak inhibitor compounds and methods |
| WO2010010189A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010188A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
| WO2010010184A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
| WO2010018874A1 (en) * | 2008-08-12 | 2010-02-18 | Takeda Pharmaceutical Company Limited | Amide compound |
| TWI453207B (zh) * | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
-
2010
- 2010-02-09 WO PCT/EP2010/051556 patent/WO2010092041A1/en not_active Ceased
- 2010-02-09 EP EP10706180A patent/EP2396324A1/en not_active Withdrawn
- 2010-02-09 CA CA2751517A patent/CA2751517A1/en not_active Abandoned
- 2010-02-09 BR BRPI1008850A patent/BRPI1008850A2/pt not_active IP Right Cessation
- 2010-02-09 US US13/201,165 patent/US20120041195A1/en not_active Abandoned
- 2010-02-09 NZ NZ594508A patent/NZ594508A/en not_active IP Right Cessation
- 2010-02-09 EA EA201101188A patent/EA201101188A1/ru unknown
- 2010-02-09 PE PE2011001470A patent/PE20120110A1/es not_active Application Discontinuation
- 2010-02-09 MX MX2011008549A patent/MX2011008549A/es not_active Application Discontinuation
- 2010-02-09 KR KR1020117018592A patent/KR20110116160A/ko not_active Withdrawn
- 2010-02-09 JP JP2011549537A patent/JP2012517971A/ja active Pending
- 2010-02-09 CN CN2010800077376A patent/CN102317288A/zh active Pending
- 2010-02-09 SG SG2011057247A patent/SG173610A1/en unknown
- 2010-02-12 AR ARP100100400A patent/AR075411A1/es not_active Application Discontinuation
-
2011
- 2011-07-15 CR CR20110386A patent/CR20110386A/es unknown
- 2011-07-28 NI NI201100151A patent/NI201100151A/es unknown
- 2011-07-29 DO DO2011000248A patent/DOP2011000248A/es unknown
- 2011-07-29 HN HN2011002095A patent/HN2011002095A/es unknown
- 2011-08-03 IL IL214426A patent/IL214426A0/en unknown
- 2011-08-03 TN TN2011000379A patent/TN2011000379A1/fr unknown
- 2011-08-09 EC EC2011011250A patent/ECSP11011250A/es unknown
- 2011-08-11 CL CL2011001947A patent/CL2011001947A1/es unknown
- 2011-08-11 CO CO11102097A patent/CO6420343A2/es not_active Application Discontinuation
- 2011-08-11 ZA ZA2011/05896A patent/ZA201105896B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012517971A (ja) | 2012-08-09 |
| IL214426A0 (en) | 2011-09-27 |
| NZ594508A (en) | 2013-12-20 |
| TN2011000379A1 (en) | 2013-03-27 |
| EP2396324A1 (en) | 2011-12-21 |
| ECSP11011250A (es) | 2011-10-31 |
| MX2011008549A (es) | 2011-12-06 |
| WO2010092041A1 (en) | 2010-08-19 |
| HN2011002095A (es) | 2014-01-06 |
| EA201101188A1 (ru) | 2012-04-30 |
| CO6420343A2 (es) | 2012-04-16 |
| CA2751517A1 (en) | 2010-08-19 |
| SG173610A1 (en) | 2011-09-29 |
| KR20110116160A (ko) | 2011-10-25 |
| US20120041195A1 (en) | 2012-02-16 |
| CN102317288A (zh) | 2012-01-11 |
| BRPI1008850A2 (pt) | 2016-03-15 |
| CR20110386A (es) | 2011-12-02 |
| NI201100151A (es) | 2012-10-03 |
| PE20120110A1 (es) | 2012-02-20 |
| ZA201105896B (en) | 2012-03-28 |
| CL2011001947A1 (es) | 2012-03-16 |
| DOP2011000248A (es) | 2011-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075411A1 (es) | Derivados de triazolo[1,5-a]piridina como inhibidores de kinasa. | |
| AU2019301944B2 (en) | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of IKAROS Family Zinc Finger 2 (IKZF2)-dependent diseases | |
| KR102394917B1 (ko) | 톨 유사 수용체 조정제 화합물 | |
| BR112020022201A2 (pt) | análogos de rapamicina ligada a c40, c28, e c-32 como inibidores de mtor | |
| ES2989617T3 (es) | Moduladores de receptores de quimioquinas y usos de los mismos | |
| ES2686097T3 (es) | Compuestos pirazolopirimidina | |
| RU2013154416A (ru) | Новые соединения и композиции для ингибирования nampt | |
| WO2018102452A3 (en) | Using substituted pyrazole compounds for treatment of hyperproliferative diseases | |
| WO2020012337A1 (en) | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases | |
| PE20190736A1 (es) | Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr) | |
| HRP20210871T1 (hr) | Piridopirimdinonski inhibitori cdk2/4/6 | |
| AR078841A1 (es) | Derivados de imidazo(1,2-b) piridazina y su uso como inhibidores de pde10 | |
| WO2020165834A1 (en) | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | |
| UA124090C2 (uk) | Інгібітори тирозинкінази | |
| MX379425B (es) | 7-bencil-4-(2-metilbencilo) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirido [3,4-e] pirimidin-5 (1h) -ona, análogos y sales del mismo y su uso en terapia. | |
| AR087471A1 (es) | Metodos de tratamiento de enfermedades degenerativas de la retina | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| PH12013502445A1 (en) | Pyridin-2 (1h) -one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases | |
| EP2967050A2 (en) | Highly active anti-neoplastic and anti-proliferative agents | |
| WO2016040848A1 (en) | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | |
| TW202237601A (zh) | 介白素-1受體相關激酶(irak)降解物及其用途 | |
| EP4477270A3 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells | |
| RU2017106489A (ru) | 6,7-дигидропиразоло[1,5-а]пиразин-4(5h)-оновые соединения и их применение в качестве отрицательных аллостерических модуляторов рецепторов mglur2 | |
| WO2024220887A1 (en) | [1,2,4]triazolo[1,5-a]pyrimidinone wrn inhibitors | |
| JP2021521262A (ja) | 免疫応答を媒介するｉｎ ｖｉｖｏでのＮＫ細胞およびＤＣ細胞の拡大 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |